Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 3 points (0.0%) at 16,165 as of Thursday, Dec. 19, 2013, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,090 issues advancing vs. 1,843 declining with 148 unchanged.

The Health Services industry currently sits down 0.2% versus the S&P 500, which is down 0.2%. On the negative front, top decliners within the industry include Insulet Corporation ( PODD), down 4.2%, DexCom ( DXCM), down 4.0%, Community Health Systems ( CYH), down 2.3%, Tenet Healthcare ( THC), down 2.1% and Universal Health Services ( UHS), down 1.7%.

TheStreet would like to highlight 4 stocks pushing the industry higher today:

4. Fresenius Medical Care AG & Co. KGaA ( FMS) is one of the companies pushing the Health Services industry higher today. As of noon trading, Fresenius Medical Care AG & Co. KGaA is up $0.37 (1.1%) to $35.10 on average volume. Thus far, 64,324 shares of Fresenius Medical Care AG & Co. KGaA exchanged hands as compared to its average daily volume of 135,900 shares. The stock has ranged in price between $34.82-$35.13 after having opened the day at $34.93 as compared to the previous trading day's close of $34.73.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, operates in the field of dialysis care and dialysis products for the treatment of end-stage renal disease. Fresenius Medical Care AG & Co. KGaA has a market cap of $20.6 billion and is part of the health care sector. The company has a P/E ratio of 17.8, equal to the S&P 500 P/E ratio of 17.7. Shares are up 1.2% year to date as of the close of trading on Wednesday. Currently there are 2 analysts that rate Fresenius Medical Care AG & Co. KGaA a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Fresenius Medical Care AG & Co. KGaA as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Fresenius Medical Care AG & Co. KGaA Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Smith & Nephew ( SNN) is up $0.44 (0.6%) to $70.15 on average volume. Thus far, 55,041 shares of Smith & Nephew exchanged hands as compared to its average daily volume of 86,100 shares. The stock has ranged in price between $69.71-$70.20 after having opened the day at $70.19 as compared to the previous trading day's close of $69.71.

Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. Smith & Nephew has a market cap of $12.3 billion and is part of the health care sector. The company has a P/E ratio of 18.2, above the S&P 500 P/E ratio of 17.7. Shares are up 25.8% year to date as of the close of trading on Wednesday. Currently there are 2 analysts that rate Smith & Nephew a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Smith & Nephew as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Smith & Nephew Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Mindray Medical International Limited ADR r ( MR) is up $0.59 (1.6%) to $38.44 on light volume. Thus far, 247,368 shares of Mindray Medical International Limited ADR r exchanged hands as compared to its average daily volume of 1.0 million shares. The stock has ranged in price between $37.41-$38.55 after having opened the day at $37.62 as compared to the previous trading day's close of $37.85.

Mindray Medical International Limited, through its subsidiary, Shenzhen Mindray, develops, manufactures, and markets medical devices worldwide. It operates in three segments: Patient Monitoring and Life Support Products, In-Vitro Diagnostic Products, and Medical Imaging Systems. Mindray Medical International Limited ADR r has a market cap of $4.5 billion and is part of the health care sector. The company has a P/E ratio of 20.8, above the S&P 500 P/E ratio of 17.7. Shares are up 15.8% year to date as of the close of trading on Wednesday. Currently there are 5 analysts that rate Mindray Medical International Limited ADR r a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Mindray Medical International Limited ADR r as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Mindray Medical International Limited ADR r Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Thermo Fisher Scientific ( TMO) is up $0.93 (0.9%) to $107.35 on average volume. Thus far, 813,205 shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $105.93-$107.38 after having opened the day at $106.41 as compared to the previous trading day's close of $106.42.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics. Thermo Fisher Scientific has a market cap of $37.0 billion and is part of the health care sector. The company has a P/E ratio of 28.2, above the S&P 500 P/E ratio of 17.7. Shares are up 66.8% year to date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, reasonable valuation levels, growth in earnings per share and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Thermo Fisher Scientific Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null